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Treatment of the elderly patient with acute 
myeloid leukaemia 
BOB LOWENBERG 
Acute myeloid leukaemia (AML) is seen at all ages, but more than half of 
the patients with AML are 60 years of age or older (Brinker, 1982, 1985). 
The incidence of AML at 60 years is approximately 4 per 100 000/year 
and at age 80 it is 15 per 100 000/year. Because of demographic changes 
and the projected increase of elderly people among the total population in 
the next decade, a significant increase in the incidence of cases of AML is 
foreseen (Liu Yin, 1993). Intensified cytotoxic therapy and bone marrow 
transplantation have improved the prognosis of AML in recent years in 
young and middle-aged adults. However, these modem approaches of 
therapy are of only little benefit o individuals of more than 60 years of 
age with AML. The causes of the differences of treatment outcome 
between middle-aged and elderly adults are probably multifactorial. 
Elderly people may suffer from AML which is a priori more resistant to 
chemotherapy. Furthermore, the abilities of aged individuals to tolerate the 
toxicity and morbidity brought along by intensive chemotherapy are 
evidently far more limited. Hence, older patients probably require treat- 
ment that is tailored to this age group. Only in recent years have specific 
efforts been made to develop therapy for the older age group. Here we 
shall briefly review the prognosis and outcome of current reatment in 
elderly patients with AML. 
REMISSION INDUCTION TREATMENT 
The initial cycles of chemotherapy always serve the objective of attaining 
a complete remission, a condition in which leukaemic cells can no longer 
be distinguished with cytomorphological or cytogenetic methods in the 
marrow, or at extramedullary sites, and in which blood cell counts recover 
to normal values. Remission induction chemotherapy usually involves a 
combination of the chemotherapeutic agents cytarabine and an anthra- 
cycline (daunomycin, idarubicin) or an anthracenedione (mitoxantrone). 
Following one or two cycles of chemotherapy a significant proportion of 
patients may enter complete remission. Should elderly patients with AML 
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actually be submitted to remission induction chemotherapy, or would it be 
preferable to refrain and offer palliative support o these individuals? The 
prevailing opinion today is that intensive chemotherapy is the treatment of 
choice for elderly patients uffering from AML, if they are fit. A palliative 
wait-and-see strategy based mainly upon haematological nd bacterio- 
logical supportive care has been directly compared with induction chemo- 
therapy in a prospective randomized study in patients of over 65 years of 
age (Lrwenberg et al, 1989). The purely supportive approach appeared a 
poor option and resulted not only in unfavourable survival but also in 
frequent hospitalization and a poor quality of life. The results of a variety 
of studies, all conducted in patients of 60 years of age or more, would 
indicate that these individuals have an approximately 50% probability of 
entering complete remission (Table 1). For comparison, as of today, among 
adults of less than 60 years, a proportion of 70% or more will attain 
complete remission following treatment with modem chemotherapy 
(Chapter 5). Thus, it is evident hat the elderly population of patients 
respond significantly less favourably to induction treatment. The inv rse 
relationship between age and complete remission rate is also apparent from 
a number of studies that enrolled patients covering a broad range of ages 
(Table 2). These results are indicative of a progressive decline in the 
response to chemotherapy with increasing age. Patients of 0-39 years, 
40-59 years, 60-84 years or 70-84 years show average response rates of 
the order of 78, 66, 45 and 35%, respectively. How can we explain these 
differences? Are they due to differences of the dose or the choice of 
chemotherapeutic agents? Or are they perhaps due to the occurrence of 
AML of greater isk in patients aged 60 years and more? Only few pros- 
pective randomized studies have addressed the question of choice of drug 
and choice of dose and revealed ifferences in efficacy. In one study (Yates 
et al, 1982) daunomycin at a 30mg/m 2 dose (in combination with 
cytarabin) produced more complete responses (47%) in patients over 60 
years as compared to a daunomycin-cytarabin schedule with a 45 mg/m 2
Table 1. Rates of complete response to induction chemotherapy in elderly patients with AML. 
Reference Patient number (n) Age Chemotherapy CR (%) 
Keating et al (1981) b 59 60+ Rub/V 49 
Kahn et al (1984)" 40 70+ DAT 28 
Rees et al (1986) b 315 60+ DAT 48 
Rees & Gray (1987) b 176 60+ DAT 43 
Ltiwenberg et al" 31 65+ DVA 58 
Arlin et al (1990) b 99 60+ DA 41 
MA 
Liu Yin et al (1991) ~ 104 60+ MA 58 
Mayer et al (1994) b 346 60+ DA 47 
Dombret et al (1995)" 173 65+ DA 59 
Stone et al (1995)' 388 60+ DA 53 
Based upon prospective trials especially designed for patients of 60 years and older. 
b Based upon prospective trials in adult patients with AML including elderly individuals. 
D = daunomycin; V = vincristine; M = mitoxantrone; CR = complete remission; A = cytarabine; 
T = thioguanine; Rub = rubidizone. 
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dose of daunomycin (31%). The better esponse rate was due to a signifi- 
cantly reduced eath rate in the daunomycin 30 mg (dauno 30) group. Also, 
doxorubicin at 30mg/m 2 in combination with cytarabine gave com- 
paratively worse results than did dauno 30. However, in contrast, in patients 
less than 60 years a dauno 45 dose produced the best response results. This 
would indicate that optimal dose selection for elderly individuals might be 
different from that in younger adults. In another study (Kahn et al, 1984) a 
reduced ose of daunomycin (50 mg/m 2on day l as compared to 60 mg/m 2
on days 1 through 3) did not result in better emission rates. In fact, the 
schedule with t e attenuated dose schedule of daunomycin resulted in a 
reduced frequency of early and aplastic mortality. However, unfortunately, 
the lower dose schedule was also associated with a reduced antileukaemic 
response rate. Apparently, when chemotherapy is reduced too much in the 
interest of tolerability, the effectivity becomes inadequate. These obser- 
vations, considered together, are clearly consistent with the notion that the 
balance between the benefits and risks of intensive chemotherapy is 
particularly delicate in older patients. Two studies addressed the question of 
the possible fficacy of mitoxantrone ascompared to daunomycin, but they 
did not provide an unequivocal nswer. In one study (Arlin et al, 1990) 
mitoxantrone permitted significantly better response rates in elderly 
patients. In contrast, in another study mitoxantrone and cytarabine as first- 
line therapy did not improve the likelihood of response (Liu Yin et al, 
1991). 
COMPLICATIONS AND MORTALITY DURING REMISSION 
INDUCTION THERAPY 
Approximately 30% of patients who do not enter emission fail due to early 
death or death during the hypoplastic phase post-chemotherapy (Table 3). 
Death occurs during hospitalization i spite of supportive care, including 
antibiotics as well as red blood cell and platelet transfusions. A majority of 
the causes of death among these individuals are due to infections. The 
greater death rate would indicate that elderly individuals are less able to 
tolerate the consequences of severe infections. They succumb more 
frequently from the negative effects on cardiac, pulmonary or renal 
function or haemodynamic dysfunction. Indeed, there is experimental 
evidence in aged animals and elderly adults to suggest that haematopoietic 
regeneration i response to phlebotomy (Boggs and Patrene, 1985) or 
bacterial challenge (Williams et al, 1986) in aged recipients is impaired. 
The inability of aged subjects to regenerate haematopoiesis in response to 
cytotoxic therapy or other perturbations and to restore the haematopoietic 
equilibrium would predict hat elderly patients with AML are less capable 
of responding to an increased haematopoietic demand and to compensate 
marrow suppression caused by cytotoxic therapy. There are also age-related 
changes that might affect he pharmacokinetics and pharmacodynamics of 
antineoplastic agents resulting in more intense or prolonged exposure 
(Balducci et al, 1989), e.g. as the result of hypoalbuminaemia, the bio- 
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availability of protein-bound agents, and therefore also the toxicity, might 
increase. Hepatic metabolism and renal excretion may diminish at higher 
age, and these changes may alter the clearance or rate of inactivation of 
drugs. The reduced marrow regenerative abilities, the reduced tolerance of 
other organs to handle the toxic effects of drugs as well as the reduced 
elimination and metabolism of drugs might all explain why elderly patients 
are at increased risk of haematopoietic and other complications from 
intensive chemotherapy. The incidence of severe infections in elderly 
patients with AML on induction therapy is approximately 20% (Stone et al, 
1995). Approximately 10% of these patients die during or within 1 week 
following completion of chemotherapy (Liu Yin et al, 1991). If one 
considers the entire induction phase including the interval of post- 
chemotherapy h poplasia pproximately 20% of patients expire (Yates et 
al, 1982; Rees and Gray, 1987; Arlin et al, 1990; Baudard et al, 1994). Thus, 
a substantial proportion of patients of over 60 years of age with AML do 
not survive remission induction therapy due to infectious or haemorrhagic 
complications during or following chemotherapy. Those who have 
experienced significant oxicity following the first cycle of chemotherapy 
are generally withdrawn prematurely from additional efforts of treatment. 
Thus, the obstacles to offering adequate th rapy to older patients with AML 
are still quite formidable. There has been hope that the haematopoietic 
growth factors may have a role in hastening haematopoietic recovery, 
reducing the incidence and severity of complications and ultimately 
reducing mortality. 
Table 3. Distribution of remission induction failures in elderly patients with AML. 
Resistant Early or 
Reference Age leukaemia (%) hypoplastic death' (%) 
Rees & Gray (1987) 60+ 15 32 
Yates et al (1982) 60+ b 9 44 
Baudard et al (1984) 60+ 45 12 
Stone et al (1995) 60+ 22 25 
Dombret et al (1995) 65+ 24 17 
Death during chemotherapy or following chemotherapy with no evidence of 
persisting AML. 
b Results of daunomycin (30 mg/m:)/cytarabine tr atment arm. 
n.r. not reported. 
CLINICAL USE OF HAEMATOPOIETIC GROWTH FACTORS 
TO MITIGATE HAEMATOPOIETIC TOXICITY 
Based on the assumption that GM-CSF or G-CSF might accelerate 
haematopoietic recovery, some studies have been conducted to explore a 
potential role for these agents. Early phase I-II studies with GM-CSF and 
G-CSF given after completion of chemotherapy in patients with AML 
indicated that there were no apparent negative ffects of growth factor 
treatment on leukaemia clearance, leukaemic regrowth or recurrence of 
leukaemia (Bettelheim et al, 1991; Btichner et al, 1991; Ohno et al, 1994), 
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even though in vitro data indicated that these factors would activate AML 
cell proliferation i culture (Ltiwenberg and Touw, 1993). Three random- 
ized studies have dealt with the use of GM-CSF after chemotherapy 
(Lrwenberg et al, submitted; Stone et al, 1995; Rowe et al, 1995). One 
other phase III study has explored apotential role of G-CSF (Dombret et al, 
1995). In all four studies (see Table 4) an enhanced regeneration of neutro- 
phils was apparent. A reduction of the length of neutropenia by 2-7 days 
was seen in G-CSF- and GM-CSF-treated patients. However, the reduction 
of the duration of neutropenia was not associated with a decrease of the 
death rate in any of these studies. In two studies, one study with GM-CSF 
(Rowe et al, 1995) and one study with G-CSF (Dombret et al, 1995) the 
complete response rate improved significantly to 60% and 70% 
respectively (Table 4). Why the complete response rate was better in only 
two of the four studies remains unexplained at the present time. In fact, the 
mortality rate was not reduced (Dombret et al, 1995; Lrwenberg et al, 
submitted; Stone et al, 1995). Only one of the studies reported a reduction 
in the percentage of resistant leukaemia (Dombret et al, 1995) that would 
have contributed to a greater response probability in case of G-CSF 
therapy. In the latter study the time to attain complete remission was also 
shortened (Dombret et al, 1995). Notably, in none of the studies were the 
days of hospitalization of the patients or the incidence of bacterial or fungal 
infections modified. Survival had not changed in patients on either G-CSF 
or GM-CSF treatment, except in one study. In the latter study the placebo- 
treated patients howed, for reasons which are not clear, a survival time 
significantly poorer than is usually seen in these patients (Rowe et al, 
1995). Thus, the accumulating results of independent phase III studies do 
not convincingly establish the clinical usefulness of G-CSF or GM-CSF 
after chemotherapy. Apparently, the haematopoietic effect of haemato- 
poietic growth factors in vivo is too limited to be exploited in the clinical 
setting. For the time being therefore the general or prophylactic use of these 
biosynthetic drugs in the standard treatment of elderly patients with AML 
cannot be recommended. In 1994, a new growth factor, thrombopoietin, has 
been cloned. This factor has now entered clinical trial. It will be of interest 
to investigate whether the clinical use of this factor in older patients with 
AML will be able to reduce the severity or length of duration of thrombo- 
cytopenia nd also make treatment in these individuals less cumbersome by 
reducing the requirements for platelet transfusion and decreasing the 
problems of platelet support in allo-immunized patients. 
RESISTANCE TO THERAPY 
Resistance of AML to chemotherapy has been a major cause of treatment 
failure in patients of over 60 years of age with AML. In a number of recent 
studies the proportion of patients howing primary resistance to chemo- 
therapy as the cause of remission induction failure was estimated at 15% or 
more (Table 3). Why would AML in elderly individuals be relatively un- 
responsive to chemotherapy? Are the intrinsic unfavourable prognostic 
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features of AML more frequently expressed in elderly patients? The answer 
to these questions is at the present ime based mainly on circumstantial 
evidence rather than on a solid set of experimental data. For instance, M0 
FAB cytological subtype (Stasi et al, 1994), unfavourable cytogenetic 
abnormalities (e.g. chromosome 5 and 7 abnormalities) (see Chapter 1), 
MDR-1 expression (Arceci, 1993; Lamy et al, 1994) (see Chapter 10), 
bcl-2 positivity (Campos et al, 1993), CD34 positivity (Geller et al, 1990; 
Guinot et al, 1991; Solary et al, 1992; Boekhorst et al, 1993a), high levels 
of autonomous proliferation i  culture (Lrwenberg et al, 1993; Boekhorst 
et al, 1993b) are all highly adverse predictors of treatment outcome. There 
are insufficient data vailable to indicate that the incidence of these poor 
risk subtypes i increased among elderly patients with AML. The results of 
some retrospective studies would suggest hat elderly patients generally 
present more often with secondary AML following myeloproliferative 
disorders and myelodysplasia (13% versus 4%) (Baudard et al, 1994). 
Favourable subtypes of AML (e.g. AML M3 1% versus 12%) and subtypes 
with unfavourable cytogenetic abnormalities are comparatively under- 
represented among patients of over 60 years of age (Baudard et al, 1994; 
Dastugue t al, 1995). This would a priori set an unfavourable stage for 
treatment outcome. AMLs evolving from a myelodysplasia as well as 
AMLs secondary to chemotherapy applied previously for another medical 
condition are generally poor-risk conditions. The myelodysplastic 
syndromes are more often seen in elderly patients and are likely to 
contribute to the increased incidence of high-risk AML in older subjects. 
AMLs developing after progression from MDS generally respond poorly to 
chemotherapy, thus providing another explanation for the unsatisfactory 
response to treatment (Keating et al, 1981; Liu Yin, 1993). 
CLINICAL USE OF HAEMATOPOIETIC GROWTH FACTORS 
TO ENHANCE CHEMOSENSITIVITY 
The probability that elderly individuals with newly diagnosed AML will 
attain a complete remission is approximately 50%. Of those who enter 
remission, the majority lose the remission status within 2 years, and only 
few become long-term survivors. Thus, recurrent disease poses a significant 
problem and is a main determinant ofunfavourable outcome. Of those who 
do not at all enter a complete remission, a significant number appear 
primarily refractory to chemotherapy. Both because of the high relapse 
probability and the high rate of primary treatment resistance attempts are 
being made to overcome resistance (Arceci, 1993). The subject of drug 
resistance is extensively discussed in Chapter 10. The haematopoietic 
growth factors have also received considerable interest because of their 
ability in vitro to enhance the killing of leukaemic blasts or leukaemic 
colony-forming cells by cytotoxic drugs. Exposure of leukaemic ells to 
cytarabine in the context of growth factor stimulation has shown an 
increase in formation of Ara-CTP, increased DNA uptake of radiolabelled 
cytarabine in leukaemic cells and, in addition, enhancement of cytotoxicity 
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(Bhalla et al, 1988; Cannistra et al, 1989; Miyauchi et al, 1989; Santini et 
al, 1990; Boekhorst et al, 1992; Hiddemann et al, 1992; Boekhorst et al, 
1994). These in vitro observations have laid the basis for introducing 
haematopoietic growth factors in clinical protocols. The simultaneous 
administration f haematopoietic growth factors in vivo with chemotherapy 
would prime the leukaemic ells and render the cells more susceptible to 
killing by cytarabine. At the present ime, clinical studies addressing the 
question of enhancement of chemotherapy effectivity by haematopoietic 
growth factors are scarce. The results of a randomized phase II study in 
patients with myelodysplastic syndromes of median age of 59 years 
submitted to daunomycin/cytarabine ch motherapy and G-CSF during 
chemotherapy, as well as post-chemotherapy, were indicative of a trend of 
better CR rates, but the difference was not significant (Ossenkoppele et al, 
submitted). In a study in elderly patients with AML of 60 years and over, 
GM-CSF was applied during and after chemotherapy, but no differences in
CR rate, relapse rate or survival were apparent in the case of GM-CSF 
therapy (Lrwenberg et al, submitted). Thus, for the time being there is no 
evidence to support a role for growth factor p iming of patients with AML, 
although the data are still scarce. One might wonder why an effect of cyto- 
toxicity enhancement that has been so apparent in vitro would not be seen 
in vivo. One explanation for the in vitro-in vivo discrepancy of growth 
factor priming of chemotherapy is that the in vitro colony-forming cells are 
not truly representative of the in vivo leukaemic re-populating progenitors, 
and therefore the in vitro data would not predict for in vivo efficacy. 
Another explanation is that the dose of growth factor applied in vivo 
(usually 5 gg/kg) is inadequate o stimulate AML progenitors fully. In fact 
it has become clear that much higher dosages of haematopoietic growth 
factors would be needed for optimal stimulation and mobilization of 
normal stem cells in vivo, and, by analogy, one might hypothesize that 
leukaemic stem ceils would likewise require significantly greater concen- 
trations of growth factor stimulation. Additional studies are clearly needed 
to clarify a potential role of the administration of HGFs for modifying cyto- 
toxicity of chemotherapeutic agents in AML. 
OUTCOME OF TREATMENT AND PROGNOSIS 
Patients aged 60 years once induced into remission are usually consolidated 
with additional cycles of chemotherapy and rarely with bone marrow trans- 
plantation or high-dose chemotherapy. Bone marrow transplants are 
currently being carried out in patients of more than 50 years with satis- 
factory results, but only infrequently in patients aged 60 years and above 
(Cahn et al, 1995). A randomized study of post-remission therapy with 
three dose levels of cytarabine (100 mg/m 2, 400 mg/m 2and 3 g/m 2) showed 
a clear dose-effect relationship in adults less than 60 years of age, but this 
relationship was not apparent in older subjects. The schedule of cytarabine 
at 3 g/m 2 resulted in significantly reduced relapse probability and superior 
survival in patients aged 60 years and below (Mayer et al, 1994). However, 
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the advantage of dose escalation of cytarabine was not apparent in older 
individuals. Therefore, high-dose chemotherapy may not be beneficial to 
the elderly with AML. Of patients of 60 years and older treated with 
chemotherapy, survival at 2 years has been estimated at approximately 20% 
(Rees et al, 1986; L6wenberg et al, 1989) and at 4-5 years at 10% or less 
(Rees et al, 1986; Liu Yin et al, 1991; Baudard et al, 1994). Median disease- 
free survival is approximately 10 months (Liu Yin et al, 1991; Baudard et 
al, 1994) and approximately 30% of patients urvive free of leukaemia t 2 
years (Rees et al, 1986; Baudard et al, 1994). Disease-free survival at 4-5 
years is of the order of 5-14% (Rees et al, 1986; Liu Yin et al, 1991; 
Baudard et al, 1994; Mayer et al, 1994). Thus, generally only a minor 
fraction of elderly patients ubmitted to intensive chemotherapy at the end 
become long-term survivors (Table 5). These results, while being meagre, 
yet represent an underestimate of disease outcome in elderly individuals 
with AML. Many patients are not referred to the hospital at all for 
chemotherapy, elect themselves not to be treated, or are considered 
ineligible to receive chemotherapy for clinical reasons. If one takes these 
patients into account, the overall prognosis of elderly patients with AML is 
far more dismal than the results of prospective studies would indicate. One 
report estimated that only approximately one-third of elderly patients were 
selected to enter treatment protocols (Baudard et al, 1994). In fact, the 
variability of patient selection leading to the inclusion of patients with 
variable risks into individual studies might help to explain the differing out- 
comes of treatment in study reports. In one study of more than 400 cases, 
an additional number of 196 patients were identified as not having entered 
into the trial (Yates et al, 1982). The single most important reason for 
exclusion of patients from trial therapy was related to the high age and poor 
clinical state of the patients. The median age of non-trial patients (67 years) 
was significantly greater than the age (53 years) of the trial group. Based on 
these considerations one might assume that the 4 year survival of elderly 
patients will be 5% or less. Therefore, the decision to treat or not to treat is 
an important choice in these individuals. It makes sense to select patients 
for induction treatment only if they are in reasonably good clinical con- 
dition. Further, one could argue that it makes sense to proceed with 
additional cycles of therapy only if they tolerate the first cycle of treatment 
with no major complications and if a haematological response to the first 
Table 5. Outcome of chemotherapy in elderly patients with AML. 
Patients Disease free Overall 
(n) (age) survival (%) survival (%) Reference 
104 60+ 15 a 10" Liu Yin et al (1991) 
108 60+ 6 b 4 b Baudard et al (1994) 
315 60+ 5 ~ l0 b Rees et al (1986) 
346 60+ 14 ° n.r. Mayer et al (1994) 
a At 44 months. 
b At 5 years. 
At 4 years. 
n.r. = not reported. 
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therapy cycle is evident. This practical approach may serve to avoid 
'overtreatment' i  elderly patients, i.e. with no benefit and at he expense of 
prolonged hospitalization. 
SUMMARY 
Individuals of 60 years living in western countries generally have a mean 
life expectancy of 20 years at least. Therefore, when aged individuals 
present with AML, it is a necessity and a challenge to treat them as 
efficiently as possible. AML is mainly a disease of the elderly and accounts 
for more than 50% of its incidence among the general population. The treat- 
ment of older individuals with AML has remained ifficult and its success 
is still limited. While in adults with AML of less than 60 years complete 
responses above 65% and survival rates of 35% are commonly obtained, 
progress in the treatment ofelderly patients has been relatively small. As of 
today, approximately 50% of older patients may be induced into remission 
with chemotherapy, and, among these complete responders, only approxi- 
mately 1 in 10 will survive free of leukaemia beyond 4 years after diag- 
nosis. In fact, on one hand, these results represent the rationale and 
motivation for offering chemotherapy to the older population. On the other 
hand, they emphasize that major obstacles to better cure rates still exist. 
These stumbling blocks apparently relate to the restricted tolerance of older 
subjects to the exposure of chemotherapy and probably also a greater 
probability of unresponsiveness of the leukaemia to cytotoxic therapy. The 
haematopoietic growth factors still hold some promise and may improve 
outcome, but for the time being there is insufficient direct evidence to 
indicate a defined and established role. It is evident hat new avenues 
should be pursued and trials specifically designed for elderly people with 
AML be conducted. These trials would need to address questions related to 
the choice of chemotherapeutic drugs (e.g. idarubicin versus mitoxantrone), 
their dose and schedule selection, the use of multidrug resistance 
modulators (to overcome intrinsic drug non-responsiveness), and the 
optimal clinical use of haematopoietic growth factors, including thrombo- 
poietin. Since trials addressing specific questions regarding the develop- 
ment of treatment of elderly patients with AML have remained scarce, the 
initiation of these studies is sorely needed. One may hope that these clinical 
trials will provide some of the necessary answers and new clues, and will 
be useful to advance future therapy of elderly AML patients. 
REFERENCES 
Arceci RJ (1993) Clinical significance of P-glycoprotein  multidrug resistance malignancies. Blood 
81: 2215-2222. 
Arlin Z, Case DC, Moore J et al (1990) Randomised multicenter t ial of cytosine arabinoside with 
mitoxantrone ordaunorubicin previously untreated adult patients with acute nonlymphocytic 
leukemia (ANLL). Leukemia 4: 177-183. 
158 B. LOWZrqBERG 
Balducci L, Parker M, Sexton W & Tantranond P (1989) Pharmacology of antineoplastic agents in the 
elderly patient. Seminars in Oncology 16- 76-84. 
Baudard M, Marie JP, Cadiou Met al (1994) Acute myelogenous leukemia in the elderly: retro- 
spective study of 235 consecutive patients. Bri ish Journal of Haematology 86: 82-91. 
Bettelbeim P,Valent P, Andreeff Met al (1991) Recombinant human granulocyte-macrophage colony- 
stimulating factor in combination with standard induction chemotherapy in de novo acute 
myeloid leukemia. Blood 77:700-711. 
Bhalla K, Birkhofer M, Arlin Z et al (1988) Effect of recombinant GM-CSF on the metabolism of 
cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2: 810-813. 
Boekhorst PAW te, L6wenberg B & Sonneveld P (1992) Stimulation by granulocyte colony stimulat- 
ing factor (G-CSF), interleukin-3 (IL-3) or granulocyte-macrophage colony stimulating factor 
(GM-CSF) enhances chemosensitivity by clonogenic acute myeloid leukemia cells. Blood 80: 
432. 
Boekhorst PAW te, Leeuw K de, Schoester M t al (1993a) Predominance of functional multidrug 
resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82: 3157-3162. 
Boekhorst PAW re, Sonneveld P & L6wenberg B (1993b) Autonomous growth and drug resistance 
mechanisms in adult acute myeloid leukemia. Exp rimental Hematology 21: 250. 
Boekhol~t PAW te, L6wenberg B & Sonneveld P (1994) Hematopoietic growth factor stimulation and 
cytarabine cytotoxicity in vitro: effects in untreated and relapsed or prim ry refractory acute 
myeloid leukemia. Leukemia 8: 1480-1486. 
Boggs DR & Patrene KD (1985) Hematopoiesis and aging III: Anemia nd a blunted erythropoietic 
response to hemorrhage in aged mice. Am rican Journal of Hematology 19: 327-338. 
Brinker H (1982) Population-based age and sex specific incidence rates in the 4 mai  types of 
leukemia. Scandinavian Journal of Haematology 29: 241-249. 
Brinker H (1985) Estimate of overall treatment results in acute non-lymphocytic leukemia based on 
age specific rates of incidence and complete remission. Cancer Treatment Reports 69: 5-11. 
Btichner Th, Hiddemann W, Koenigsmann M et al (1991) Recombinant human granulocyte- 
macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid 
leukemia t higher age or after relapse. Blood 78" 1190-1197. 
Cahn JY, Labopin M, Mandelli F et ai (1995) Autologous bone marrow transplantation for first 
remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of 
the European Bone Marrow Transplant Group. Blood 85: 575-579. 
Campos L, Rouault JP, Sabido O et al (1993) High expression of bcl-2 protein i  acute myeloid 
leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096. 
Cannistra SA, Groshek P & Griffin JD (1989) Granulocyte-macropbage colony-stimulating factor 
enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and nthe 
myeloid blast crisis phase ofchronic myeloid leukemia. Leukemia 3: 328-334. 
Dastugue N, Payen C, Lafage-Pochitaloff Met ai (1995) Prognostic significance of karyotype in de 
novo adult acute myeloid leukemia. Leukemia 9: 1491-1498. 
Dombret H, Chastang C, Fenaux P et al (1995) A controlled study of recombinant human granulocyte 
colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. 
New England Journal of Medicine 332: 1678-1683. 
Geller RB, Zahurak M, Hm~itz CA et al (1990) Prognostic importance of immunophenotyping in 
adults with acute myelocytic leukaemia: th  significance of the stem-cell glycoprotein CD34 
(My 10). British Journal of Haematology 76: 340-347. 
Guinot M, Sanz GF, Sempere Aet al (1991) Prognostic value of CD34 expression in de novo acute 
myeloblastic leukemia. British Journal of Haematology 15: 533-534. 
Hiddemann W, Kiehl M, Zfihlsdorf Met  al (1992) Granulocyte-macrophage colony-stimulating 
factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of 
leukemic blasts and thecytotoxic effect of clonogenic cells from patients with acute myeloid 
leukemia. Seminars in Oncology 19:31-37. 
Kahn SB, Begg CB, Mazza JJ et al (1984) Full dose versus attenuated dose dannomycin, cytosine 
arabinoside and 6-thio-guanine in the treatment ofacute nonlymphocytic leukemia in the elderly. 
Journal of Clinical Oncology 2: 865-870. 
Keating MJ, Mc. Credie KB, Benjamin RS et ai (1981) Treatment of patients over 50years of age 
with acute myelogenous leukemia with a combination of rubidizone and cytosine arabinoside, 
vincristine and prednisone (ROAP). Blood 58: 584-590. 
Lamy T, Goasguen JE, Mordelet E et ai (1994) P-Glycoprotein (P-170) and CD34 Expression in adult 
acute myeloid leukemia (AML). Leukemia 11: 1879-1883. 
TREATMENT OF AML IN THE ELDERLY 159 
Liu Yin JA (1993) Acute myeloid leukaemia in theelderly: biology and treatment. British Journal of 
Haematology 83: 1-6. 
Liu Yin JA, Johnson PRE, Davies JM et al (1991) Mitozantrone and cytosine arabinoside as first-line 
therapy in elderly patients with acute myeloid leukemia. British Journal of Haematology 79: 
415-420. 
L6wenberg B, Zittoun R, Kerkhofs H et al (1989) On the value of intensive remission-induction 
chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase 
III study of the EORTC Leukemia Group. Journal of Clinical Oncology 1:1268-1274. 
L6wenberg B & Touw IP (1993) Hematopoietic growthfactors and their eceptors in acute leukemia. 
Blood 81:281-292. 
L6wenberg B, Putten WLJ van, Touw IP et al (1993) Autonomous proliferation of leukemic cells in 
vitro as a determinant of prognosis in adult acute myeloid leukemia. New England Journal of 
Medicine 328:614--619. 
LSwenberg B, Suciu S, Zittoun R et al (1995) GM-CSF during as well as after induction chemother- 
apy (CT) in elderly patients with acute myeloid leukemia (AML). The EORTC-HOVON phase 
III trial (AML 11). Blood 86 (supplement 10): 43 (abstract). 
Mayer R J, Davis RB, Schiffer CA et al (1994) Intensive postremission chemotherapy in adults with 
acute myeloid leukemia. NewEngland Journal of Medicine 331: 896-903. 
Miyauchi J, Kelleher CA, Wang CH et al (1989) Growth factors influence the sensitivity of leukemic 
stem cells to cytosine arabinoside in culture. Blood 73: 1272-1278. 
Ohno R, Naoe T, Kanamaru A et al (1994) A double-blind controlled study of granulocyte colony- 
stimulating factor started two days before induction chemotherapy in refractory acute myeloid 
leukemia. Blood 83: 2086-2092. 
Ossenkoppele G J, Verhoef GEG, Bolt B v.d. etal (1995) Randomized phase II study on the value of 
G-CSF (filgrastim) in combination with standard induction chemotherapy in myelodysplastic 
syndromes (MDS). Blood 86 (supplement 1): p 338a (abstract). 
Rees JKH, Gray RG, Swirsky D & Hayhoe FGJ (1986) Principal results of the medical research 
council's 8th acute myeloid leukemia trial. Lancet i i: 1236--1241. 
Rees JKH & Gray R (1987) Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE 
consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial. 
Seminars in Oncology 14: 32-36. 
Rowe JM, Andersen JW, Mazza JJ et al (1995) A randomized placebo-controlled phase III study of 
granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) 
with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E 1490). 
Blood 86" 457-462. 
Santini V, Nooter K, Delwel R & L6wenberg B (1990) Susceptibility of acute myeloid leukemia 
(AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment 
in vitro after stimulation with colony stimulating factors (CSFs). Leukemia Research 14: 
377-380. 
Solary E, Casanovas RE, Campos Let  al (1992) Surface markers in adult acute myeloblastic 
leukemia: correlation of CD19+, CD34+ and CD14+/DR- phenotypes with shorter survival. 
Leukemia 6: 393-399. 
Stasi R, Poeta GD, Venditti A etal (1994) Analysis of treatment failure in patients with minimally 
differentiated acute myeloid leukemia (AML-M0). Blood 83: 1619-1625. 
Stone RM, Berg DT, George SL et al (1995) Granulocyte-macrophage colony-stimulating factor after 
initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N w 
England Journal of Medicine 332: 1671-1677. 
Williams LH, Udupa KB & Lipschitz DA (1986) Evaluation of the effect of hematopoiesis in 
C57BL/6 mouse. Experimental Hematology 14: 827-832. 
Yates J, Glidewell O, Wiernik Petal (1982) Cytosine arabinoside with daunomycin or adriamycin for 
therapy of acute myelocytic leukemia: a CALGB study. Bloo  60: 454-463. 
